首页> 外国专利> USE IN SINGLE PILL/TABLET/CAPSULE MINOCYCLINE, FLUCONAZOLE AND ATORVASTATIN IN THE TREATMENT OF AUTOIMMUNE DISEASES OF TYPE RELAPSING REMITTING MULTIPLE SCLEROSIS OR PROGRESSIVE AIMED AT IMPROVING THE QUALITY 'OF LIFE AND CONTEXT OF DISABILTITY SCALE EDSS

USE IN SINGLE PILL/TABLET/CAPSULE MINOCYCLINE, FLUCONAZOLE AND ATORVASTATIN IN THE TREATMENT OF AUTOIMMUNE DISEASES OF TYPE RELAPSING REMITTING MULTIPLE SCLEROSIS OR PROGRESSIVE AIMED AT IMPROVING THE QUALITY 'OF LIFE AND CONTEXT OF DISABILTITY SCALE EDSS

机译:在单药丸/片剂/胶囊中的吗啉,氟康唑和阿托伐他汀用于治疗缓解多发性硬化症的疾病或进展性自身疾病,以改善生活质量和残疾程度的背景

摘要

The present invention has for object the use of minocycline or its equivalent forms, or of any form of tetracycline in combination with Fluconazole or any of its equivalent form with antifungal capacity and atorvastatin or any equivalent form (lipophilic statins) for the preparation of a single compound directed to the treatment of every type of multiple sclerosis or diseases etiopathologically equivalents, whether it be of remitting relapsing or progressive, but anyway degenerative kind, considering the weaker of subject that will receive it as consequence of previous treatments or state of illness. The effectiveness of this combination has been shown from many researches on single components. To date, given the proven efficacy of the individual components, the low toxicity of the same and the long period of the marketing thereof, as well as the observed greater efficiency of the combination of the same used in accordance with the overexposed new mode of use, it can be said that the above-mentioned new compound derived from a combination of minocycline or its equivalent forms, or of any form of tetracycline in combination with Fluconazole or any of its equivalent form with antifungal capacity and atorvastatin or any equivalent form (lipophilic statins), is effective in reduce the incidence of the disease on quality of life of the patient with the designed dosage that never has been determined before.
机译:本发明的目的是使用米诺环素或其等效形式,或任何形式的四环素与氟康唑或其任何具有抗真菌能力的等效形式和阿托伐他汀或任何等效形式(亲脂性他汀)的组合。该化合物可用于治疗各种类型的多发性硬化症或疾病,在病因学上与疾病相当,无论是复发性还是进行性疾病,但无论如何都是退化性疾病,考虑到先前治疗或疾病状态较弱的受试者都将接受治疗。从对单个组件的许多研究中已经证明了这种组合的有效性。迄今为止,考虑到各个成分的有效功效,相同成分的低毒性和长期的销售,以及根据过度暴露的新使用方式观察到的相同成分组合的更高效率, ,可以说上述新化合物衍生自米诺环素或其等效形式的组合,或任何形式的四环素与氟康唑或其任何具有抗真菌能力的等效形式和阿托伐他汀的组合或任何等效形式(亲脂性)他汀类药物)可有效降低疾病的发病率,并以前所未有的设计剂量降低患者的生活质量。

著录项

  • 公开/公告号CA2958057A1

    专利类型

  • 公开/公告日2016-02-11

    原文格式PDF

  • 申请/专利权人 DE SILVESTRI FABRIZIO;

    申请/专利号CA20142958057

  • 发明设计人 DE SILVESTRI FABRIZIO;

    申请日2014-08-06

  • 分类号A61K31/65;A61K47/55;A61K31/40;A61K31/4196;A61P21;A61P25/28;

  • 国家 CA

  • 入库时间 2022-08-21 14:21:17

相似文献

  • 专利
  • 外文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号